Bringing about 20 years of experiences in anti-tumor drug development, Yu Wang, M.D./Ph.D., is responsible for the strategic planning and operation of GenFleet's clinical development as Chief Medical Officer. His expertise focuses on anti-tumor therapeutics, and his experiences cover the development of chemotherapy agents, targeting agents, therapeutic vaccines, oncolytic virus therapies, checkpoint inhibitors and cell therapies treating solid tumors and hematological malignancies.
Dr. Wang received a doctorate degree in Surgery from Shanghai Medical University (now School of Medicine, Fudan University), and completed postdoctoral training at Barbara Karmanos Cancer Institute（Wayne State University, Michigan）. In China, he worked with multinational pharmaceutical companies (Eli Lilly, GSK, Sanofi APTSU and Novartis) directing full clinical development of oncology products. As a program leader of Translational Clinical Oncology at Novartis, Dr. Wang took part in the clinical studies of several innovative drugs later approved globally. Prior to his role at GenFleet, he was the co-founder of ZenRhyme Advisory, serving as a part-time Chief Medical Officer or senior consultant for biotech and pharmaceutical companies.
